Gilead and GSK are the most noteworthy giants on the antiviral drug market, which together accounted for 68.9% market share thereof in the world in 2017. This article summarizes and compares the noteworthy enterprises and antiviral drugs on the antiviral drug market, and concludes that HIV drugs will become the key to deciding the share on the antiviral drug market, with the decline of the HCV direct-acting antivirals (DAAs).
HIV drugs to become the key to deciding the share on the antiviral drug market
The HCV cure rate has witnessed an unprecedented increase thanks to the excellent efficacy of the DAAs, while the sales of the anti-HCV drugs have been rapidly declining. On the other hand, the HIV drug sales are fast rising and becoming the key to deciding the share on the antiviral drug market, as HIV patients’ life time is extended and life quality improves.
Gilead is a very typical example. Take the data of Gilead’s financial reports in 2016 and 2017 for instance,